Evidence map›Paper›PMID 26584666›Full record

ArticleTropical medicine & international health : TM & IH2016

CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.

Christopher J Hoffmann, Jean Maritz, Gert U van Zyl

Abstract read
In one paragraph

Article in Tropical medicine & international health : TM & IH, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Christopher J HoffmannJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Jean MaritzNational Health Laboratory Service, Tygerberg, Cape Town, South Africa.
Gert U van ZylNational Health Laboratory Service, Tygerberg, Cape Town, South Africa.

Funding

Latent reservoir characterization and correlations with neurocognitive functioninR01MH105134 · NIMH · STELLENBOSCH UNIVERSITY · PI COTTON, MARK FREDRIC · 2014 to 2018
$3.1M
Characterizing HIV-1 diversity, evolution, and integration sites in children initiating cART in early infectionU01CA200441 · NCI · STELLENBOSCH UNIVERSITY · PI KEARNEY, MARY, VAN ZYL, GERT UVES · 2015 to 2019
$842k
CAUSES OF AND ASSOCIATIONS WITH DEATH DURING LONG TERM HAART IN AFRICAK23AI083099 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HOFFMANN, CHRISTOPHER J · 2010 to 2014
$671k
NCI NIH HHS U01 CA200441NIAID NIH HHS K23 AI083099NIMH NIH HHS R01 MH105134
6 · The paper itself

Abstract

objectiveCD4 count decline often triggers antiretroviral regimen switches in resource-limited settings, even when viral load testing is available. We therefore compared CD4 failure and CD4 trends in patients with viraemia with or without antiretroviral resistance.

methodsRetrospective cohort study investigating the association of HIV drug resistance with CD4 failure or CD4 trends in patients on first-line antiretroviral regimens during viraemia. Patients with viraemia (HIV RNA >1000 copies/ml) from two HIV treatment programmes in South Africa (n = 350) were included. We investigated the association of M184V and NNRTI resistance with WHO immunological failure criteria and CD4 count trends, using chi-square tests and linear mixed models.

resultsFewer patients with the M184V mutation reached immunologic failure criteria than those without: 51 of 151(34%) vs. 90 of 199 (45%) (P = 0.03). Similarly, 79 of 220 (36%) patients, who had major NNRTI resistance, had immunological failure, whereas 62 of 130 (48%) without (chi-square P = 0.03) did. The CD4 count decline among patients with the M184V mutation was 2.5 cells/mm(3) /year, whereas in those without M184V it was 14 cells/mm(3) /year (P = 0.1), but the difference in CD4 count decline with and without NNRTI resistance was marginal.

conclusionOur data suggest that CD4 count monitoring may lead to inappropriate delayed therapy switches for patients with HIV drug resistance. Conversely, patients with viraemia but no drug resistance are more likely to have a CD4 count decline and thus may be more likely to be switched to a second-line regimen.

Indexed as

CD4 Lymphocyte CountDecision MakingDrug MonitoringDrug Resistance, ViralViral LoadAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedRetrospective StudiesSouth AfricaAnti-HIV Agentsadherenceadherenciacompliancecritères d’échec immunologiquedétermination de la charge virale du VIH-1fallo inmunológicofirst-line antiretroviral therapyHIV-1 drug resistanceHIV-1 viral load testingimmunologic failure criteriaM184VM184V, Major NNRTI drug resistance mutationsmutaciones de resistencia a medicamentos NNRTImutations NNRTI de résistance majeure aux médicamentsprueba de carga viral VIH-1résistance aux médicaments du VIH-1resistencia a medicamentos VIH-1terapia antirretroviral de primera líneatraitement antirétroviral de première ligne

Identifiers

PMID26584666
PMCPMC6717435

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.